Plasma

Early indicators: Investigational convalescent plasma is safe for patients with COVID-19

Via Mayo Clinic News Network “Mayo Clinic and collaborators today reported safety data on the first 5,000 hospitalized patients transfused with investigational convalescent plasma as part of the Food and Drug Administration’s national Expanded Access Program (EAP) for COVID-19. The early indicators suggest experimental convalescent plasma is safe in treating severely ill patients. At this time, convalescent plasma […]

You Survived COVID-19, You Could Help Others Do the Same

Via Takeda “Experts from the world’s leading plasma companies have come together to create a new alliance aimed at treating the new coronavirus. The CoVIg-19 Plasma Alliance is an initiative to accelerate the development of a potential treatment for COVID-19. The first phase of the Alliance is collecting plasma at licensed plasma collection centers across […]

UnitedHealth Group Donates $5 Million to Support a Federal Program Developing Treatments for COVID-19

UnitedHealth Group is donating $5 million to support a federally sponsored program seeking to accelerate and expand the availability of investigational convalescent plasma treatments for COVID-19 patients nationwide. The initiative, led by Mayo Clinic, coordinates efforts to collect blood plasma from donors who have recovered from COVID-19 and distribute the plasma to hospitalized patients with […]

Mayo looks for plasma donors for a ‘hopeful’ strategy

Via Post Bulletin “Joyner suggested that the speed involved in putting the trial together was nothing short of remarkable. What usually takes 18 months in terms of setting up the trial has taken 18 days.” “The task is being tackled with a sense of urgency because of the contagious nature of the virus. Minnesota health officials […]

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

Via Takeda Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with […]

Sandstone Diagnostics Raises Additional Series A Financing to Accelerate Zero Delay™ Plasma Technology Development

New Product Line Expands Company’s CentriFluidic™ Product Portfolio ZD is poised to dramatically improve both the patient blood collection process as well as the performance of clinical laboratory tests. Karen Drexler, CEO, Sandstone PLEASANTON, CA, USA, May 6, 2019 /EINPresswire.com/ — Sandstone Diagnostics, a medical device company committed to making high quality clinical testing ubiquitous, is […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER